Grigorii Nos

Title: Grigorii Nos: Innovator in Tumor Microenvironment Research

Introduction

Grigorii Nos is a prominent inventor based in Moscow, Russia. He has made significant contributions to the field of immunotherapy, particularly in understanding tumor microenvironments. With a total of 2 patents, his work is paving the way for advancements in cancer treatment.

Latest Patents

Grigorii Nos's latest patents focus on tumor microenvironment-based methods for assessing CAR-T and other immunotherapies. These patents detail methods for determining whether a subject is likely to respond to adoptive cell therapies, such as chimeric antigen receptor (CAR) T-cell therapy. The methods involve identifying a subject's tumor microenvironment (TME) type based on a molecular-functional expression signature. Additionally, the patents include steps for determining the lymphoma microenvironment (LME) type of lymphoma subjects, such as those with Diffuse Large B Cell Lymphoma (DLBCL), and assessing their prognosis based on this determination.

Career Highlights

Grigorii Nos is currently associated with Bostongene Corporation, where he continues to innovate in the field of cancer research. His work is instrumental in developing personalized treatment approaches for patients undergoing immunotherapy.

Collaborations

Grigorii collaborates with notable colleagues, including Georgy Sagaradze and Anna Gribkova. Their combined expertise enhances the research efforts at Bostongene Corporation.

Conclusion

Grigorii Nos is a key figure in the advancement of immunotherapy through his innovative research on tumor microenvironments. His contributions are vital for improving treatment outcomes for cancer patients.